-
Benzinga's Top Pre-Market NASDAQ Losers
Tuesday, May 24, 2011 - 8:25am | 157Identive Group Inc (NASDAQ: INVE) dipped 12.59% to $2.57 in the pre-market session. INVE announced offering to sell shares of its common stock in an underwritten public offering in the US. Huntington Bancshares Inc (NASDAQ: HBAN) dropped 1.89% to $6.23 in the pre-market trading. Huntington...
-
Deutsche Bank Provided Color on Valeant Pharmaceuticals' Acquisition of Sanitas
Tuesday, May 24, 2011 - 7:19am | 336Deutsche Bank provided color on Valeant Pharmaceuticals (NYSE: VRX) after the company announced it will acquire Sanitas, a Lithuanian-based generic drugs manufacturer. In a research report published today, Deutsche Bank states, "Very early this morning, Valeant has agreed to acquire Lithuanian-...
-
Valeant Pharmaceuticals To Acquire AB Sanitas For $442.9 Million
Tuesday, May 24, 2011 - 4:28am | 170Valeant Pharmaceuticals International Inc (NYSE: VRX) announced its plans to acquire Lithuania-based AB Sanitas for around 314 million euros ($442.9 million) in cash. The transaction also includes 50 million euros of Sanitas debt. The deal is likely to immediately add to Valeant's results. The...
-
Parkinson's Disease Bacteria Link Discovered: Companies Looking for a Cure
Monday, May 23, 2011 - 11:04pm | 444Researchers at the Louisiana State University Health Sciences Center have discovered a link between Parkinson's disease and the bacteria Helicobacter pylori, more commonly known as H. pylori. This is the same bacteria that can cause stomach ulcers. The study showed that middle aged mice infected...
-
Spying on Elite Funds - Part 1
Monday, May 23, 2011 - 6:54pm | 2396It was a beautiful long weekend in Montreal. I tried to enjoy it as much as possible getting out of the house every chance I got. Even went out with some buddies of mine on Saturday night and came back in the wee hours of the morning. Haven't stayed up that late in a long time and of course, paid...
-
Eli Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement
Monday, May 23, 2011 - 4:21pm | 76Eli Lilly and Company (NYSE: LLY) today announced that it has signed agreements with private investors Care Capital and NovaQuest Capital to establish BioCritica Inc., a newly-formed and privately-held biotechnology company. BioCritica, based in Central Indiana, will initially focus on the...
-
Medtronic Earnings Preview: Modest Growth Seen for 4Q and FY 2011
Monday, May 23, 2011 - 10:39am | 224Medtronic (NYSE: MDT) is scheduled to report fiscal fourth-quarter 2011 results before the markets open tomorrow, May 24. Analysts expect the medical device maker to announce that per-share earnings inched up 3 cents from a year ago to $0.93. That consensus estimate is unchanged from 60 days ago....
-
Lilly and Investor Group Form New Critical Care Company BioCritica, Sign Xigris License Agreement
Monday, May 23, 2011 - 10:02am | 171Eli Lilly and Company (NYSE: LLY) today announced that it has signed agreements with private investors Care Capital and NovaQuest Capital to establish BioCritica. BioCritica, based in Central Indiana, will initially focus on the continued U.S. development and commercialization of Xigris, Lilly's...
-
Par Pharmaceutical to Acquire Edict Pharmaceuticals for Up to $37.6M
Monday, May 23, 2011 - 8:30am | 118Par Pharmaceutical Companies, Inc. (NYSE: PRX) announced today that it entered into a definitive agreement to acquire privately-held Edict Pharmaceuticals, an India-based developer and manufacturer of generic pharmaceuticals, for up to $37.6 million in cash and Par's repayment of certain additional...
-
Benzinga's Top Pre-Market NASDAQ Gainers
Monday, May 23, 2011 - 8:20am | 158Identive Group Inc (NASDAQ: INVE) shares advanced 9.87% to $3.34 in the pre-market session. INVE and RFID industries signed a Value Added Reseller (VAR) agreement with NXP Semiconductors (NASDAQ: NXPI). Spectrum Pharmaceuticals Inc (NASDAQ: SPPI) shares advanced 3.58% to $8.97 in the pre-market...
-
J.P. Morgan Reports on Mylan
Monday, May 23, 2011 - 7:36am | 132In a report released today, J.P. Morgan commented on Mylan (NASDAQ: MYL). In the report, J.P. Morgan was positive in its assessment of the company. J.P. Morgan writes, " With a highly diversified business that we believe is capable of delivering high-teens EPS growth over the next several years,...
-
Piper Jaffray Overweight On Salix Pharmaceuticals
Monday, May 23, 2011 - 7:30am | 175Piper Jaffray has an overweight rating and a $47 price target on shares of Salix Pharmaceuticals (NASDAQ: SLXP). In a note to investors, Piper Jaffray writes, "We attended the American Pain Society meeting, where positive long-term data for Salix/Progenics' Relistor (methylnaltrexone) in chronic...
-
Mylan Launches Generic Version of Depakote Sprinkle Capsules
Monday, May 23, 2011 - 7:02am | 61Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Pharmaceuticals Inc. has launched Divalproex Sodium Capsules USP, 125 mg, the generic version of Abbott's Depakote® Sprinkle Capsules, a treatment for certain types of seizures. Divalproex Sodium Capsules had U.S. sales of...
-
Merger Arbitrage Mondays – May 23, 2011
Monday, May 23, 2011 - 2:08am | 4780Merger activity increased last week with five new deals announced and seven closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: Total Number of Deals Closed in 2011 74 Total Number of Deals...
-
Pfizer Announces SUTENT Receives U.S. FDA Approval For Advanced Pancreatic Neuroendocrine Tumors
Friday, May 20, 2011 - 4:08pm | 62Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration has approved SUTENT as the first anti-VEGF therapy to treat progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable locally advanced or metastatic disease. Pancreatic NET is a...